On Wednesday, Boston Scientific Corporation (NYSE:BSX) released the results of the primary endpoint of the ACURATE IDE trial of ACURATE neo2 Aortic Valve System for patients with severe ...

Boston Scientific continues to work closely with the U.S. Food and Drug Administration on the regulatory strategy for approval of the ACURATE valve platform in the U.S. The ACURATE neo2 Aortic ...

A pacemaker is a small, battery-powered device implanted in your chest to help regulate your heart rate. It consists of two main parts—a pulse generator and leads. Pulse generator: This contains the ...

Boston Scientific Corporation (NYSE ... which received FDA approval in the quarter and our EMPOWUR leadless pacemaker, which ...

Marlborough-based Boston Scientific increased its estimated net sales growth for 2024. Meanwhile, Thermo Fisher slightly raised its full-year adjusted earnings per share guidance. Boston ...

Erica Denhoff / Icon Sportswire via Getty Images Boston Scientific shares fell Wednesday as its third-quarter profit missed estimates. The medical device maker's adjusted earnings per share and ...

Good morning and welcome to the Boston Scientific Third Quarter 2024 Earnings ... FDA approval in the quarter and our EMPOWUR leadless pacemaker, which we now have submitted to the FDA.

Boston Scientific (NYSE:BSX) shares were down 5% in morning trading Wednesday following news that the company has paused a study for its new FARAPULSE Pulse Field Ablation system due to unforeseen ...

JEAN DAWSON “Glimmer of God,” the just-released fourth full-length from this California singer, songwriter, and arranger, is full of ambition and nerve, blending influences from R&B, power ...

Core Scientific is expanding its AI deal with CoreWeave. Russell Cann, Core Scientific’s chief development officer, talked to CoinDesk about the particulars of the bitcoin miner’s multi ...

Boston Scientific is keeping the ball rolling in pulsed field ablation, posting 177% electrophysiology growth in the third quarter powered by the launch of its Farapulse system for atrial ...

Boston Scientific reported Q3 revenue of $4.21 billion, beating estimates. EPS reached $0.63, surpassing consensus of $0.59. Cardiovascular sales rose 25%, and MedSurg increased 10.3% ...